IPSIS Encourages Excellus Blue Cross Blue Shield to Cover RFA for Knee Osteoarthritis

On February 11, 2020, IPSIS offered evidence to Excellus Blue Cross and Blue Shield in support of coverage for radiofrequency ablation (RFA) of the genicular nerves to treat pain associated with knee osteoarthritis. The Society’s comments refute classification of these procedures as investigational and advocate for coverage in appropriately selected patients.

Members may click here 🔒 to read the IPSIS comment letter.

Given the strength and quality of the evidence in support of the safety and effectiveness of genicular nerve RFA, Category I CPT codes were adopted 🔒 by the Centers for Medicare and Medicaid Services (CMS) effective January 1, 2020.